Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:CASNumber |
1616392-27-6
|
| gptkbp:developedBy |
gptkb:Corcept_Therapeutics
|
| gptkbp:hasMolecularFormula |
C27H28F3NO4
|
| gptkbp:hasSMILES |
CC1(C2CCC3(C(C2C1)C4=CC=C(C=C4)F)C(=O)N(C3)C)C
|
| gptkbp:hasUNII |
6Q1K1Q1K0E
|
| https://www.w3.org/2000/01/rdf-schema#label |
Miricorilant
|
| gptkbp:isInvestigationalDrugFor |
gptkb:metabolic_syndrome
antipsychotic-induced weight gain |
| gptkbp:IUPACName |
(4aR,6aR,6bS,8aR,10aS,10bR,12aS)-6b-(4-fluorophenyl)-4a,6a,8a,10a,12a-hexamethyl-2,3,4,5,6,6a,6b,7,8,8a,9,10,10a,10b,11,12-hexadecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]oxazol-2-one
|
| gptkbp:mechanismOfAction |
glucocorticoid receptor antagonist
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL4297592
71587741 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:CORT118335
|
| gptkbp:bfsParent |
gptkb:Corcept_Therapeutics
|
| gptkbp:bfsLayer |
7
|